Year | Age (years) | Source | AQP4 | NFL | CXCL13 | CaMK II | D1 | D2 | MOG | Alb quota |
|---|
2012 | 22 | Serum | – | – | – |
132
|
8000
|
32,000
| – | – |
2012 | 22 | CSF | – | – | – |
209
| 250 | 250 | – | 3.7 |
2014 | 24 | Serum |
1:100
| – | – | 109, 99 | Negative | Negative | Negative | – |
2014 | 24 | CSF | Negative | 300 |
44
| – | | – | Negative | 3.6 |
2015 | 25 | Serum |
1:10
| – | – | – | – | – |
1:32
| – |
2015 | 25 | CSF | |
400
|
167
| – | – | – | Negative | 4.4 |
2018 | 28 | Serum |
1:10
| – | – | – | – | – | – | – |
2018 | 28 | CSF | Negative | 370 | 3 | – | – | – | – | 3.1 |
- Abbreviations: Alb quota Ratio between albumin concentration in CSF (mg/L) and serum (g/L) (reference < 6), AQP4 Aquaporin-4 antibody, NMO Neuromyelitis optica (IgG) (reference negative), NFL Neurofilament light protein (reference < 380), CSF Cerebrospinal fluid, CXCL13 Chemokine (C-X-C motif) ligand 13, also known as B-cell-attracting chemokine 1 (BCA-1) (reference < 7.8), CaMK II Ca2+/calmodulin-dependent protein kinase II (positive > 130%), D1 Dopamine receptor antibody positive > 2000, D2 Dopamine 2 receptor antibody positive > 8000, MOG Myelin oligodendrocyte glycoprotein (IgG) (reference negative)
- Positive values are presented in bold
